Estrella Immunopharma Inc. (ESLA) Stock Forecast & Price Target
Estrella Immunopharma Inc. · NASDAQ
$0.73-0.00 (-0.41%)
15-min delayed · Aug 26, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering Estrella Immunopharma Inc, 1 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $8.00 to $8.00, so the covering firms are broadly aligned. The average target of $8.00 sits 996% above the current $0.73. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near 0% this year and 0% next, consensus EPS building from about $-0.07 next quarter toward $-0.32 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Strong Buy
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to Estrella Immunopharma Inc.
As of Aug, 1 of 1 firms rate ESLA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ESLA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.07
Range $-0.07 – $-0.07 · 1 analysts · +600% YoY
Next period, 1 analysts expect Estrella Immunopharma Inc. to earn $-0.07 a share (range $-0.07 – $-0.07), versus $-0.01 a year earlier. Full-year consensus is $-0.29, growing to $-0.32 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Estrella Immunopharma Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ESLA.
#1
Jason Kolbert
D. Boral Capital · Rank #407
Buy
$8.00+995.9% to target
Overall win rate
22%
+ Follow
ESLA stock forecast FAQ
What is ESLA's average 12-month price target?+
The 1 analysts with a live target average $8.00 for Estrella Immunopharma Inc. over the next 12 months, ranging from a $8.00 high to a $8.00 low.
Is ESLA stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 1 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover ESLA?+
1 analysts have an active rating on Estrella Immunopharma Inc., and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering ESLA?+
Among analysts who currently cover ESLA, Jason Kolbert of D. Boral Capital has the strongest overall Quantellect track record (Rank #407). Their current call is Buy with a $8.00 target.
What is Estrella Immunopharma Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.07 per share (range $-0.07 – $-0.07) across 1 analysts. Full-year EPS is projected at $-0.29, rising to $-0.32 the following year.
How much revenue is Estrella Immunopharma Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading ESLA lately?+
As of Aug, 1 of 1 firms rate ESLA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ESLA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
